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ABSTRACT 
Background: Major trauma is a leading cause of morbidity and mortality worldwide with hemorrhage 
accounting for 40% of deaths.  Acute Traumatic Coagulopathy (ATC) exacerbates bleeding but controversy 
remains over the degree to which inhibition of procoagulant pathways (anticoagulation), fibrinogen loss and 
fibrinolysis drive the pathological process. Through a combination of experimental study in a murine model of 
trauma hemorrhage (TH) and human observation our objective was to determine the predominant 
pathophysiology of ATC.   
Methods: First, a prospective cohort study of 300 trauma patients admitted to a single level 1 trauma center with 
blood samples collected on arrival.  Second, a murine model of ATC with suppressed Protein C activation via 
genetic mutation of thrombomodulin.  In both studies analysis for coagulation screen, aPC levels and ROTEM 
were performed.   
Results: In patients with ATC we have demonstrated elevated aPC levels with profound fibrinolytic activity and 
early depletion of fibrinogen.  Procoagulant pathways were only minimally inhibited with preservation of 
capacity to generate thrombin.  Compared to Factor V and VIII, proteases which do not undergo aPC-mediated 
cleavage were reduced but maintained within normal levels.  In transgenic mice with reduced capacity to 
activate PC, both fibrinolysis and fibrinogen depletion were significantly attenuated.  Other recognised drivers 
of coagulopathy were associated with less significant perturbations of coagulation.   
Conclusions: APC associated fibrinolysis and fibrinogenolysis, rather than inhibition of procoagulant 
pathways, predominate in ATC.  In combination these findings suggest a central role for the Protein C pathway 
in ATC, and provide new translational opportunities for management of major trauma hemorrhage. 
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INTRODUCTION 
Trauma is a major global public health issue causing nearly six million deaths worldwide each year.1  
Hemorrhage is responsible for approximately half of these deaths and is the leading cause of preventable death 
after injury.2,3  Bleeding is exacerbated by Acute Traumatic Coagulopathy (ATC) which is present immediately 
on hospital admission in up to 25% of severely injured patients.4-6  ATC is associated with a four-fold increase 
in mortality, more severe organ injury and higher transfusion requirements.5-7 Resuscitation strategies targeted at 
ATC have shown potential to dramatically reduce death from injury, possibly mediated by early reversal of 
coagulopathy.8  However, controversy exists over the precise mechanism of ATC and the balance between 
inhibition of procoagulant pathways (anticoagulation or consumption), fibrinogen loss and fibrinolysis.9-13 
Failure to define the pathophysiology of ATC has prevented identification of the optimal therapeutic 
intervention for early traumatic coagulopathy and remains an important research priority for trauma care.  
  
ATC is a clinical syndrome14 evident soon after injury4,5,15, characterised predominantly by functional 
reductions in clot generation and clot strength with only minor prolongations in clotting times16. Biomarker7,17,18 
and animal studies19 have highlighted the pathogenic contributions of shock and tissue injury in ATC17,20 
suggesting an endogenous process resulting in systemic anticoagulation, hyperfibrinolysis7,10,21,22 and fibrinogen 
depletion23,24.  It is postulated that thrombin is switched from a pro- to anticoagulation function with diversion 
from fibrin generation towards increased production of activated PC (aPC)7,17,25 and subsequent cleavage of 
Factors Va and VIIIa.  In excess aPC consumes plasminogen activator inhibitor-1 (PAI-1) and releases 
fibrinolysis from inhibitory control with consequent rise in tissue plasminogen activator (tPA) and plasmin7,26.  
Tissue injury itself is associated with increased thrombin generation27, release of tPA from the endothelium and 
activation of the fibrinolytic system28.  Some hypothesise these early derangements after trauma haemorrhage 
represent Disseminated Intravascular Coagulation (DIC) with a fibrinolytic phenotype13 and propose the early 
fibrinogen loss is a direct result of fibrinogenolysis10. With a lack of mechanistic confirmation, the interplay 
between thrombin generation, anticoagulation, fibrinogen availability and hyperfibrinolysis in ATC remains 
unclear.  Shock and tissue injury both independently promote fibrinolysis but in combination, through the 
release of aPC, could in theory provide the stimulus for massive systemic fibrinolytic activity and potentially 
unify the apparent opposing theories of ATC. 
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The overall objective of this combined prospective human cohort study of trauma patients and experimental 
model of trauma hemorrhage, was to determine the role of aPC in ATC and specifically quantify the balance 
between inhibition of procoagulant pathways (anticoagulation), fibrinogen loss and fibrinolysis.  This study 
builds on our previous evaluation of the downstream elements of fibrinolysis in ATC21, with emphasis on 
mechanistic study rather than clinical outcome, in a detailed examination of functional coagulation and 
biomarkers of both procoagulant and fibrinolytic pathways.  The first aim was to functionally characterise ATC 
with measurement of aPC levels in trauma patients to determine the relationship between aPC, procoagulant 
factors, thrombin generation and fibrinolysis.  Second, we wished to characterise the relationship of plasma aPC 
levels with markers and mediators of fibrinolytic activation in humans. Third, we aimed to mechanistically 
confirm the role of aPC in a murine model of trauma hemorrhage to understand the effects of genetic 
modulation of the PC pathway on clot formation, fibrinolysis and fibrinogenolysis. Finally, we report outcomes 
for trauma patients with ATC stratified by aPC levels soon after injury.   
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METHODS 
 
Human study design 
Single center, prospective, cohort study of trauma patients presenting directly to a level 1 trauma center (January 
2007 - June 2009).  The study is part of the Activation of Coagulation and Inflammation in Trauma (ACIT) 
research programme.  We have previously published data from the same cohort on functional measures of 
coagulation16 and fibrinolysis21.  ACIT is approved by the UK National Research Ethics Committee (East 
London and the City, London, UK).  Patient consent was in accordance with the Mental Capacity Act (England; 
2005) for inclusion of incapacitated patients into emergency medical research using a Professional Consultee 
(independent physician).   
 
Patient Sampling and Data Collection 
All adult trauma patients (>15 years) meeting local criteria for full trauma team activation were eligible for 
enrolment and recruited when research personnel present (08:00-22:00 daily).  ACIT inclusion/exclusion 
criteria, data collection, blood sampling, assays and outcome measures have been previously reported21.  A 20-
mL research sample of blood was drawn from either the femoral vein or antecubital fossa, and the standard 
trauma laboratory tests were performed within 20 min of arrival in the ED. Blood for ROTEM analysis was 
drawn into a 2.7-mL citrated vacutainer (0.109 M buffered sodium citrate, 3.2%; Becton Dickinson, Plymouth, 
UK). Samples for PT determination were collected in 4.5-mL glass vacutainers (0.109 M buffered sodium 
citrate, 3.2%; Becton Dickinson), 9:1 (v/v). The sample for hemostatic assays and thrombin generation was 
placed in a citrated tube, and spun down within 2 h of blood draw. The sample was first spun at 1750g for 10 
min; the supernatant was then extracted, and respun at 1750g for a further 10 min. The extracted plasma was 
stored in aliquots at -80°C. Arterial blood analysis for base deficit (BD) was performed simultaneously with the 
research sample collection.  Assays for coagulation factors were complete in 99-100% of patients. Plasma 
samples for biomarkers requiring ELISA analysis were incomplete in 3% of cases except for aPC which could 
not be quantified in 7% of patients.     
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Samples were analysed at the conclusion of the study with an automated analyser (Sysmex CA-CS2100i 
System, Siemens AG, Germany) to measure coagulation Factor activity [normal range]: II [78-117], V [66-114], 
VII [50-150] VIII [52-153], IX [58-138], X [50-150], XI [50-150], XIII [70-140], von Willebrand Factor (vWF) 
[50-160], Protein C (PC) [75-134], Antithrombin (AT) [80-130].   Enzyme linked immunosorbant assays were 
used to quantify tissue plasminogen activator (tPA; Asserachrom tPA, Diagnostica Stago, France) (normal range 
2–12 ng/mL); prothrombin fragments 1+2 (PF 1+2; Enzygnost F1+2 monoclonal, Siemens Healthcare 
Diagnostics, Germany) (normal range 69-229 pmol/L); plasmin-α2-antiplasmin complex (Plasmin-Antiplasmin; 
DRG Plasmin-Antiplasmin micro, Germany) (normal range 120-700 µmol/L); aPC (EIA, Surgical Research 
Laboratory, University of California, San Francisco General Hospital, USA [1-3ng/ml]). PT and Clauss 
fibrinogen were processed by the central hospital laboratory along with a standard full blood count (FBC). 
Prothrombin ratio (PTr) was calculated as observed PT divided by mean normal PT for the reagent used.   
 
ATC was defined using ROTEM (EXTEM) – Amplitude (of clot) 5 minutes (A5) after Clotting Time (CT) 
based an earlier study demonstrating that low CA5 and Maximum Clot Firmness (MCF) were the viscoelastic 
hallmarks of ATC16.  Additional EXTEM parameters reported were EXTEM assays, Clot Formation Time 
(CFT), Alpha angle and Maximum Clot Firmness (MCF).  Prolongation of PT is associated with coagulopathy 
clinically and PTr >1.2 was used for comparison between human and animal studies.16,20  Hypoperfusion was 
defined as base deficit (BD) >6mEq/l29,30  FVIII:vWF ratio calculated to reflect the differential inhibition by 
aPC.  Blood for aPC analysis was collected into protease inhibitors (P100 - Becton Dickinson, Plymouth, UK) 
and measured using ELISA31.  Protein C circulates in plasma at 70 nM as the zymogen of the anticoagulant 
serine protease, activated protein C (aPC), which averages 40 pM (∼ 2.3 ng/mL +/- 0.2ng/ml) in normal 
plasma32.  Kaiser et al33 reported in vitro inhibition of clotting at 10 ng/ml aPC and for convenience we divided 
groups into four with the aPC <3ng/ml representing normal range.  Thrombin generation was measured via 
calibrated automated thrombogram (CAT) using standard protocol34 in duplicate in a Fluoroskan Ascent® 
reader (thermo Labsystems, Helsinki, Finland; filters 390nm excitation and 460 nm emission).  Thrombin 
generation curves and the area-under-the-curve (endogenous thrombin potential, ETP) were calculated using 
Thrombinoscope™ software (Thrombinoscope BV, Maastricht, Netherlands).    
 
Outcome measures 
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Patients were followed until hospital discharge or death.  For mortality analysis patients surviving to hospital 
discharge were assumed to still be alive.  Outcome measures were recorded for 28-day ventilator-free days, 
blood transfusion requirements in the first 12 hours and length of critical care and overall hospital stay.  
 
Animal study design 
To mechanistically verify the clinical findings in humans we analysed coagulation profiles of experimental 
models of trauma hemorrhage. Wild type (WT) mice and transgenic thrombomodulin knock-in (TMKI) mice 
with reduced capacity to activate PC were compared.  In addition we evaluated ATC in homozygous mice for 
Factor V Leiden who are resistant to aPC mediated cleavage.  A novel murine model for ATC was developed 
based on the experimental procedure previously reported in a rat model of trauma hemorrhage20 .  All mice were 
cared for in accordance with the UK Home Office Guidance in the Operation of the Animals (Scientific 
Procedures) Act 1986.  General anaesthesia was induced and maintained with spontaneous respiration of 
isoflurane carried in medical air. Animals were placed supine on a heated anaesthesia platform and body 
temperature was maintained at 37 ± 1 °C by means of a rectal probe attached to a homeothermic blanket 
(Harvard Apparatus). The left carotid artery and external jugular vein of all animals were catheterised with 
polyethylene tubing (Portex) connected to a pressure transducer (Capto SP 844, AD instruments) and syringe 
pump (PHD 22/2000, Harvard Apparatus). Fluid was continuously infused at a rate of 50 µl per hour through 
the carotid catheter with supplementary flushes as required in order to maintain patency.  
 
Mice in the trauma haemorrhage group received a 2-cm paramedian laparotomy, closed in one layer with 7-mm 
surgical clips (Harvard Apparatus) and bilateral mid-shaft closed tibia and fibula fractures. The experimental 
period commenced immediately after traumatic injury or 7 min after completion of carotid catheterization (the 
mean time taken to complete traumatization).  Animals were then bled from an average mean arterial pressure of 
91 mmHg (MAP) to a target of 25–30 mmHg over a period of 60 min and this pressure was maintained by 
further withdrawals as necessary. 
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Study randomisation and blinding was ensured by using a predefined  alternated  assignment of animals to 
experimental groups and the use of identification codes with respect to the WT and the TMKI groups throughout 
the experimental intervention and data analysis (both with a C57/B6 phenotype). For FVL studies the genetic 
background was revealed at the end of the study. 
 
Factor V Leiden 
During the experimental period the genetic background was unknown. V Leiden mice (Strain B6.129S2-
F5tm2Dgi/J, Jackson Laboratory, Bar Harbor, Main, USA) are knock-out in a C57BL/6 background, expressing 
factor VR504Q, resistant to activated protein C proteolysis. When performing the data analysis the background 
was revealed: 14 mice were WT, 15 were V Leiden heterozygous (HT) and 15 were homozygous (mutant -MT). 
 
Transgenic inhibition of aPC  
Homozygote TMPro ‘knock-in’ (TMKI) mice with thousand-fold reduced capacity to activate PC (Blood 
Research Institute of Wisconsin, Milwaukee, USA) bred from C57/B6 mice after targeted mutagenesis with a 
single amino acid substitution (Glu404Pro) for the thrombomodulin receptor.  26 TMKI mice underwent 
laparotomy and trauma hemorrhage to MAP 25–30 mmHg for 60 min (TMKI TH).  The same protocol was 
performed in 26 experimental controls (C57/B6 TH). A further mice of each genotype were anaesthetised and 
monitored for 60 min to act as sham controls (anaesthestised/monitored): TMKI sham (n=12) and C57/B6 sham 
(n=12).   
 
Sampling technique & analysis 
50µl blood/saline aspirated from the carotid catheter of all animals and discarded. 200µl aspirated into 1 ml 
syringe pre-filled with 20µl 3.2% sodium citrate (Sigma, UK) to achieve 1:9 concentration. Lactate measured 
(Accutrend, Roche) and the remainder centrifuged at 3500g for 15 minutes.  Plasma supernatants were aspirated 
and immediately frozen in liquid nitrogen before storage at -80°C.  Citrated blood analysed using pediatric 
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ROTEM cups and ELISA for D-dimer (USCN Life Sciences Inc, Wuhan, China) and fibrinogen (Genway 
Biotech, San Diego, CA). 
 
Statistical analysis 
Patients with ATC were compared with those presenting without ATC for clinical characteristics and 
coagulation profiles. The relationship between aPC, functional coagulation (ROTEM) and key coagulation 
factors was then evaluated.  Next key biomarkers of the fibrinolytic pathway were examined to determine their 
relationship to aPC and known control mechanisms e.g. PAI-1, tPA.  Finally, associations between admission 
aPC level and clinical outcomes were explored.  In the experimental models the effect of genetic modulation of 
the PC pathway was determined through analysis of aPC and functional parameters of coagulation (ROTEM).  
Finally the role of the Protein C pathway in the murine model and impact of impaired thrombomodulin 
generation on fibrinolysis, fibrinogen and mortality was examined.  
 
The human study was based on the existing available data from a convenience sample. For the experimental 
models, sample size was calculated with statistical power of 90% and significance level α =0.05 to detect a 25% 
difference in mortality from a baseline mortality rate of 20% in a murine model of trauma haemorrhage35 and 
20% difference in ROTEM parameters based on a previous animal study in ATC20.  Normal quantile plots were 
used to test for Normal distribution.  Parametric data is expressed as mean ±95% confidence intervals.  All non-
parametric data is presented as median (interquartile range, IQR) and analysed using a two tailed Mann Whitney 
U test.  Univariate linear regression was performed using best-fit model for calculation of R2 values. Two-group 
analysis was performed using a two-tailed, unequal variance Student’s t test.  Multi-group analysis was 
performed using one-way ANOVA with Dunnett’s post hoc correction or two-way ANOVA with Bonferroni’s 
post test between subjects for determining interaction with elevated levels of aPC.  χ2 test was used for 
dichotomous data analysis.  Survival analysis in the murine model was performed by deriving Kaplan-Meier 
plots and curves compared using the log rank test (Mantel-Haenszel method. Significance level was set at 
p<0.05 and all statistical analysis was performed using GraphPad Prism version 5.00 for Windows, GraphPad 
Software, San Diego California USA.  
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RESULTS 
There were 325 patients enrolled into the human study over the 19-month period.  ROTEM sample analysis was 
incomplete in three patients, consent was not obtained in 15 cases and there were seven retrospective exclusions 
leaving 300 patients available for analysis.  Median age was 33 (23-48) years, 82% were male and 21% 
presented following penetrating trauma.  Patients had sustained significant trauma with median ISS 10 (4-25) 
and 41% were severely injured (ISS>15).  Average time from injury to blood sampling was 86 (69-112) 
minutes, 9 (5-14) minutes from arrival in ED.  On arrival 15% of patients were severely shocked (BD >6 
mEq/L), 17% coagulopathic by ROTEM definition (A5 ≤35mm) and 9% with PTr >1.2 (median PT 11.2 [10.8-
11.9] seconds).  Minimal intravenous fluid was administered prior to baseline sample collection was 0 (0-400) 
ml and no patient received artificial colloid or vasoactive agents prior to venepuncture.  Overall mortality was 
8%.  We retrospectively analysed the deaths of 25/26 patients from electronic archives – seven patients died 
from exsanguination, six from multiple organ dysfunction (MODS) or sepsis and 12 from traumatic brain injury.  
Mean admission aPC levels in survivors were 1.8 +/-0.6 ng/ml.  Patients that died early (<24 hours) from 
haemorrhage had significantly higher aPC levels on admission compared to those who died after 24hrs from 
MODS or sepsis, early haemorrhagic deaths: aPC 30ng/ml vs MODS/sepsis deaths: aPC 8ng/ml (p<0.05).   
 
Human study (mechanistic investigation) 
In this study, patients with ATC (A5 ≤35mm) had aPC levels over five times higher than those with normal 
coagulation (Table 1).  Elevated aPC was associated with a significant concentration-dependent decrease in 
ROTEM parameters of clot strength (Figures 1A and 1B) and prolongation of PTr (aPC <3ng/ml: PTr 1.0 [1.0-
1.0] vs aPC >9ng/ml: PTr 1.3 [1.2-1.4], p<0.001).  ATC has been shown to be associated with early PC 
depletion7 and we now demonstrate that a reduction in PC activity is associated with high aPC (aPC ≤3ng/ml: 
PC activity 91% vs. aPC >9ng/ml: PC activity 65%, p<0.001).  Activated PC was elevated only in the presence 
of shock (BD>6 mmol/l), (BD >6mmol: aPC: 9 (5-13) ng/ml vs. BD <3mmol/l: 1 (0-1) ng/ml, p<0.001).   
 
Activated PC is known to inactivate coagulation Factors V and VIII and can result in systemic anticoagulation.  
Factor V has the greatest reduction in activity in ATC (average 32% reduction, Table 1). High aPC levels in 
trauma patients were associated with a 50% reduction in FV activity (Figure 1C).  85% of patients with FV 
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<50% had A5 ≤35mm (p<0.001) and progressive loss of FV was associated with a concentration-dependent 
reduction of ROTEM clot strength (see Supplemental Digital Content 1A – figure showing association of falling 
Factor V level with reduced A5).  Similarly, the FVIII:vWF ratio was significantly reduced as aPC levels 
increased suggesting a relative inhibition of FVIIIa (Figure 1D).  However, preservation of Factor V activity did 
not fully protect against coagulopathy in trauma.  Reduced Factor V is not sufficient to inhibit procoagulant 
pathways as endogenous thrombin potential (ETP) is maintained regardless of aPC concentration (Figure 1E).  
Consequently, in trauma patients aPC is not associated with any significant increase in CT (Figure 1F) and 
prolongation in PTr was only observed when 3x normal (>9 ng/ml).  This suggests that the reduced FV/VIII 
levels associated with aPC cannot fully explain the observed functional coagulation changes in ATC.  Together 
these data suggest that systemic aPC-induced anticoagulation is not the primary mechanism in ATC. 
 
Levels of procoagulant factors which are not targets of aPC mediated cleavage were preserved in ATC.  FII, 
FVII, FIX and FX activity were all maintained at >80% (see Supplemental Digital Content 1B – figure of aPC 
levels and FII, FVII, FIX and FX activity) and thrombin generation was in fact twofold higher in the ATC 
cohort (Table 1).  Widespread consumption of procoagulant factors and reduced thrombin generating capacity 
does not appear to be a major cause of ATC.  Procoagulant factor activity (sampled in pH buffered assays) was 
minimally affected by the degree of metabolic acidosis with levels preserved above 80% at BD>6 mmol/l (see 
Supplemental Digital Content 1C – figure of coagulation Factor levels stratified by BD).  Hemodilution with 
intravenous fluids produced minimal effects on coagulation and low haematocrit was not associated with any 
significant changes in clot strength (see Supplemental Digital Content 1D – figure showing no change in A5 
with respect to changing hematocrit).  In patients receiving >1000ml fluid before sampling, procoagulant factors 
were all maintained above 80% with relative preservation of fibrinogen levels (0ml: Fibrinogen 2.17g/dl vs. 
>1000ml: Fibrinogen 1.82g/dL, p<0.05) (see Supplemental Digital Content 2 – table of coagulation Factor 
levels stratified by amount of fluid administered).  Patients given intravenous fluids had only minor changes in 
clotting parameters and haemodilution in isolation does not appear to be an important mechanism for ATC.   
 
Average fibrinogen levels were significantly lower in the ATC cohort (A5 ≤35mm) (1.35 [1.19-1.51] g/L vs. A5 
>35mm: 2.23 [1.53-2.93] g/L, p<0.05) and this 40% reduction in fibrinogen levels was a greater reduction than 
any other procoagulant factor (Table 1).  Despite very high thrombin generation, fibrinogen levels were 
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maintained above critical levels while aPC was normal, suggesting that consumption is not the primary 
mechanism of fibrinogen loss (Figure 2A).  High levels of aPC were associated with low fibrinogen levels 
(Figure 2B) and reduced functional fibrinogen activity (FIBTEM) (Figure 2C).  There was a trend towards 
fibrinogen reduction to critical levels (<1.5g/dL) in association with high thrombin generation, only in the 
presence of elevated aPC, p=0.08 (Figure 2A).  Currently it is not possible to accurately quantify 
fibrinogenolysis independent of fibrinolysis, however Plasmin-Antiplasmin levels were inversely correlated 
with fibrinogen (R2 =0.24, p<0.01).  In patients with low fibrinogen (<1.5g/L), Plasmin-Antiplasmin levels were 
15 times the upper limit of normal and significantly higher than patients with normal fibrinogen (Fibrinogen 
<1.5g/L: Plasmin-Antiplasmin 10739 μg/L vs. Fibrinogen >1.5g/L: Plasmin-Antiplasmin 2734 μg/L, p<0.01).   
 
High aPC was associated with increased fibrinolysis as indicated by elevated Plasmin-Antiplasmin levels (aPC 
≤3ng/ml: Plasmin-Antiplasmin 2221 ±392μg/L vs aPC >9ng/ml: Plasmin-Antiplasmin 18955 ±3861μg/L, 
p<0.001).  This tPA dependent process was completely inhibited at normal aPC levels but was massively 
activated when aPC was high (Figure 2D).  Mechanistically aPC is known to consume PAI-1 when in excess, 
and there was a trend towards reduced PAI-1 in trauma patients with high aPC (>9ng/ml) (Figure 2E).  
Fibrinolysis is known to co-activate with thrombin generation through its direct induction of tPA release. 
However we were clearly able to show that, as with fibrinogenolysis, thrombin generation associated 
fibrinolytic activity (D dimer production) in ATC is significantly higher in the presence of elevated aPC levels 
(Figure 2F).   
 
Human study (outcomes) 
Patients with ATC had increased mortality: PTr>1.2 (52%) and A5≤35mm (26%). Consistent with our previous 
study7, high aPC on admission was strongly associated with increased all-cause mortality (see Supplemental 
Digital Content 3A – figure).  Patients with aPC >9 ng/ml had a mortality of 68% compared to 2% for those 
with normal aPC levels (p<0.001).  There was a concentration-dependent relationship between aPC and 
transfusion requirements for both PRBC and FFP (see Supplemental Digital Content 3B – figure).  Patients 
requiring a massive transfusion (10+ PRBC units) had significantly higher aPC levels compared with those 
receiving PRBC <10 units: aPC 20 (15-25) ng/ml vs. 3 (3-3) ng/ml (p<0.001).  High aPC was associated with 
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longer hospital median length of stay (aPC >9ng/ml: 30 days vs. aPC ≤3ng/ml: 5 days, p<0.001).  Patients with 
elevated aPC on admission required significantly more days in ICU (see Supplemental Digital Content 3C – 
figure) and had fewer ventilator-free days at 28 days (aPC >9ng/ml: 2 days vs. aPC ≤3ng/ml: 5 days, p<0.001).  
Increased aPC is associated with excess mortality and morbidity in ATC.  
 
Murine studies 
Trauma hemorrhage was associated with significantly higher aPC levels in WT mice compared to Sham animals: 
10.3 (7.8-12.7) ng/ml vs. 1.5 (1.2-1.8) ng/ml (p<0.001) (Figure 3A).  TMKI mice had a minor increase in aPC 
levels and were relatively protected from ATC after trauma hemorrhage for 60 minutes.  In comparison to WT, 
clot strength (MCF) was well preserved (Figure 3B and Supplemental Digital Content 4 - table) with 
significantly less marked prolongations of PT and APTT (Supplemental Digital Content 4 - table).  
Homozygous mice for Factor V Leiden when subjected to TH had similar prolongations in CT (Figure 3C) and 
clot generation (Figure S3) compared with WT animals.  In support of the findings in humans, there was only a 
minor prolongation in CT (20%) in WT mice and no change in TMKI animals subjected to trauma hemorrhage 
(Figure 3D).  As with WT animals, Factor V Leiden mice after trauma hemorrhage had significant delays in clot 
formation (CFT) and reductions in clot strength, albeit to a slightly lesser extent than WT (see Supplemental 
Digital Content 5 - figures).  In this experimental model a reduction in endogenous capacity to activate PC was 
protective against ATC in mice whilst preserved Factor V function did not fully prevent ATC.    
 
Confirming the observation seen in humans of apparent aPC-related fibrinolytic activity, WT mice after 60 
minutes of trauma hemorrhage exhibited a three-fold increase in D-Dimer levels which was completely 
abolished in the TMKI variants (Figure 4A).  In the murine model, fibrinogen was observed to fall by over a 
third after trauma hemorrhage in WT mice (T0: 1.86g/L vs. T60: 1.25g/L, p<0.05) but TMKI animals were 
protected from this fibrinogen depletion with only a non-significant reduction in fibrinogen after trauma 
hemorrhage (Figure 4B).  Mortality rates in TMKI mice were almost half that of WT mice subjected to TH (WT: 
42.3% vs TMKI: 23.1%, p<0.05) with longer median survival times (Figure 4C).     
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DISCUSSION 
In both clinical and experimental studies we have demonstrated that aPC may be a unifying link in the current 
opposing hypotheses of early traumatic coagulopathy.  Building on previously published data from our human 
cohort study21, this work completes a detailed evaluation of the procoagulant and fibrinolytic systems in ATC, 
highlighting a potential central mechanism for aPC with mechanistic confirmation in an experimental model of 
trauma haemorrhage.  Patients with ATC had elevated aPC levels, found fibrinolytic activity and early depletion 
of fibrinogen yet with only minimal inhibition of procoagulant pathways (factor loss) and preserved thrombin 
generation.  Fibrinogen was significantly reduced in association with elevated levels of aPC with no evidence to 
support a systemic consumptive process to explain this early depletion.  ATC, in particular fibrinolysis and 
fibrinogen depletion, were both significantly attenuated following trauma hemorrhage in transgenic mice with 
reduced capacity to activate PC. These results add further evidence to earlier work highlighting the importance 
of the PC pathway7,18,35-37  and in a murine model provide mechanistic confirmation of aPC with respect to 
fibrinogen loss and fibrinolysis in ATC.      
  
In the early stages after injury, generation of aPC appears to be of greater importance than other classical 
mediators of traumatic coagulopathy (haemodilution, acidosis, clotting factor consumption).  Dilution of plasma 
alters the dynamics of thrombin generation by relative reductions in both pro and anti-coagulant factors.38.  
Paradoxically dilution actually increases thrombin generation until plasma proteins are reduced below 40% of 
normal.27  Consistent with this observation we have shown that relatively small volumes of intravenous fluids 
had some minimal effect on clot amplitude.  However in vitro measurements of clot strength in the presence of 
hemodilution may not be true representation of clot integrity in vivo.  An increased proportion of plasma in the 
ROTEM cup produces an apparent increase in clot strength although hemodilution will simultaneously reduce 
the platelet count and clot strength. Platelet counts were well preserved above 150 despite hemodilution but aPC 
levels were significantly higher in patients receiving large amounts of crystalloids.   The effects of dilution may 
therefore be confounded by the degree of shock, which we have shown is associated with increased aPC 
production.  APC was associated with selective depletion of Factors V and VIII but no reduction in the capacity 
to generate thrombin and hence with only minimal effects on PTr.  These findings are consistent with a recent 
study demonstrating no difference in endogenous thrombin potential between severely injured patients and 
healthy controls.39  In FVL mice, resistant to aPC-mediated cleavage of V, ATC was still observed following 
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trauma hemorrhage, therefore inhibition of procoagulant pathways (anticoagulation) cannot fully account for 
functional changes of haemostasis after major trauma.  Thrombin generation and platelet count in patients with 
ATC were normal with no clear evidence of widespread consumption of clotting factors.  This is supported by 
Johansson and colleagues who in a study of 80 severely injured and shocked trauma patients were unable to 
identify any overt disseminated intravascular coagulation according to ISTH criteria.11  ATC is defined 
predominantly by diminished clot strength but preservation of procoagulant pathways and thrombin generation.    
 
Procoagulant factors are maintained at near normal levels and are unlikely to be responsible for the observed 
prolongation of PT or reductions in A5 and MCF.  The mechanism for diminished clot strength and increased 
clotting times must therefore involve fibrinogen, consistent with other recent investigations of alternative 
mechanisms for early traumatic coagulopathy.10,40,41  We have previously shown that fibrinogen reduction is a 
principle component of ATC 16,24 with both retrospective data42,43 and a pilot randomised controlled trial of 
cryoprecipitate44 demonstrating an association between early replacement and improved outcome.  Fibrinogen 
levels were reduced significantly in the human study to levels below transfusion guidelines for replacement 
(<1.5g/dL).45  In the experimental model, TMKI mice were protected against significant fibrinogen depletion in 
contrast to WT, suggesting an aPC related process is responsible for early loss.  Currently, the critical level for 
haemostatic function is unknown and potential mechanisms for loss of fibrinogen remain to be elucidated24,45 
although indirect evidence for fibrinogenolysis has been demonstrated in alternative models of TH.10  In this 
study activation of the fibrinolytic system was marked and occurred in association with elevated aPC and 
appeared to be a tPA related process with consumption of PAI-1.  Genetic modulation of the PC pathway was 
protective in the TMKI with significant attenuation of fibrinolysis following TH.  Plasmin can directly induce 
fibrinogenolysis46 and together these novel findings suggest production of aPC early after trauma hemorrhage, 
may release both fibrinolysis and fibrinogenolysis from inhibitory control to give rise to systemic clot lysis and 
direct breakdown of fibrinogen. 
 
High levels of aPC on admission were associated with increased mortality, longer hospital stay and increased 
transfusion requirements. 70% of patients that died early did so from exsanguination and had significantly 
higher aPC levels on admission compared to those who died later from MODS or sepsis.  APC levels in these 
patients dying from MODS were three times normal suggesting early activation of PC, with subacute depletion 
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may be a risk factor for later sepsis and organ failure17.  Low protein C levels have been reported several hours 
or days after injury36,37,47 and patients who develop ventilator acquired pneumonia have persistently low plasma 
levels of PC in the immediate period after trauma.36  PC depletion after sepsis is well reported48,49 with 
thrombotic microvascular organ injury50 and may contribute directly to cell dysfunction and death.51  In trauma 
early depletion of PC would result in a procoagulant state with insufficient cytoprotective mechanisms and 
theoretically would predispose to septic complications and organ injury, as reported by Cohen and colleagues.36  
 
There are several limitations to this study.  First, the endothelium and thrombocytes are fundamental to both 
coagulation and inflammation with the platelet membrane of central importance to clot assembly.  We did not 
measure platelet function in this study and our results are therefore based on plasma protein levels.  At present 
the role of platelets in ATC pathophysiology remains unknown.  In light of the results from the PROPPR study 
and potential outcome benefits of early platelet transfusion, endogenous function and aggregation capacity of 
transfused platelets should be a key focus of research.  Second, our definition of ATC (A5 ≤35mm) is based on 
earlier work which functionally characterised it by reduced clot strength rather than prolonged clotting times16.  
Patients meeting this definition will therefore more likely have lower fibrinogen levels and possibly reduced 
platelet function and/or count.  Third, we were unable to measure activated FV and FVIII to assess direct effects 
of aPC.  However, increased loss of FVa and FVIIIa by aPC mediated cleavage will produce reciprocal 
reductions in FV and FVIII through alterations in the pharmacokinetics of the enzymatic reaction.  Fourth, it is 
not possible to quantify separately fibrinogenolysis secondary to lysis by plasmin or cleavage by thrombin and 
therefore we are only able to show by process of elimination the likely mechanism of fibrinogen depletion. The 
coagulation response to prolonged shock, continued hemorrhage and the effects of transfusion form part of an 
on-going study.  In the early phase of the ACIT study which to date has recruited over 2500 patients 
internationally, we did not capture mode of death although this is now embedded in the study protocol.   Finally, 
the human cohort study was completed over five years ago during which time the fields of trauma induced 
coagulopathy and transfusion science have advanced greatly.  The robust and early blood sampling in this study 
does however ensure validity of the study objectives to examine the early endogenous changes in coagulation.    
 
The findings of this study have important clinical implications.  There are currently no therapeutic options for 
ATC beyond procoagulant administration i.e. plasma, which is known to be poorly effective at correcting 
18 
 
coagulopathy52,53 and the anti-fibrinolytic tranexamic acid54. But if the predominant pathophysiologic model 
converges on activation of PC, this may suggest a potential disadvantage to early administration of plasma 
which provides a source of plasminogen and protein C, both substrates for fibrinolytic pathways.  However this 
assumption must be balanced against the role of plasmin inhibitors e.g. alpha 2 anti-plasmin, contained within 
plasma and their beneficial effects in ATC.  We have previously reported preliminary results which demonstrate 
that early high dose FFP elicits a variable response in the coagulation system41.  If aPC related-fibrinolysis and 
fibrinogen depletion are the primary problems then augmenting thrombin generation may further drive PC 
activation with negative effects on clot function and exacerbate bleeding.  Although plasma contains important 
inhibitors of plasmin i.e. alpha 2 antiplasmin, resuscitation with products which lack plasminogen and protein C 
i.e. cryoprecipitate or fibrinogen concentrate, require further study as they may have a more favourable 
therapeutic profile than those which contain Protein C (plasma and prothrombin complex concentrates).     
 
In summary ATC is defined predominantly by increased fibrinolytic activity and rapid depletion of fibrinogen.  
We have now shown that the Protein C pathway provides a mechanistic link between the two main theories of 
early trauma coagulopathy – ‘Disseminated Intravascular Coagulation with fibrinolytic phenotype’ 13 and 
primary aPC driven fibrinolysis (and possible fibrinogenolysis)7.  Patients with raised aPC had a dose-dependent 
reduction in clot strength and evidence of increased fibrinolytic activity yet normal thrombin generation.  The 
mechanistic confirmation of fibrinolysis as a central component of ATC supports clinical evidence from cohort 
studies55-57 and randomised controlled trials54 that early empiric administration of an antifibrinolytic improves 
outcomes in trauma.   Fibrinogen was depleted early through a non-consumptive (systemic) process, 
theoretically by fibrinogenolysis through the direct action of plasmin.  Elevated aPC was associated with worse 
outcomes and increased transfusions following major trauma.  A unifying hypothesis defined by aPC generation 
and widespread fibrinolytic activation provides new translational opportunities for treating this important global 
disease.  Effective reversal of ATC may require novel treatment strategies directed at ameliorating activation of 
PC and subsequent depletion of PC stores with targeted replenishment of fibrinogen.       
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FIGURE LEGENDS 
Figure 1 
HUMAN STUDY – activated Protein C (aPC) is associated with concentration dependent functional 
changes in coagulation but preservation of thrombin generation: ROTEM is EXTEM unless specified. 
ANOVA with Dunnett’s post hoc correction.  (A) Elevated aPC in trauma patients are associated with 
diminished A5 *p<0.05 vs. normal aPC (≤3 ng/ml).  (B) Maximum Clot Firmness falls in the presence of high 
aPC in trauma patients *p<0.05 vs. normal aPC (≤3 ng/ml).  (C) Factor V (FV) falls in association with 
increasing aPC in trauma patients *p<0.05 vs. normal (aPC ≤3 ng/ml).  (D) Inverse relationship between von 
Willebran Factor (vWF): Factor VIII (FVIII) ratio and elevated aPC indicative of selective inhibition of FVIII 
activity in humans following severe injury *p<0.05 vs. normal (aPC ≤3 ng/ml).  (E) Endogenous Thrombin 
Potential (ETP) remains unchanged in trauma patients regardless of Factor V level.  (F) Only minimal (non-
significant) prolongation of Clotting Time (CT) is observed with high levels of aPC in trauma patients.     
 
Figure 2  
HUMAN STUDY - Fibrinogen loss and fibrinolysis are only observed in association with elevated activated 
Protein C (aPC) levels: One-way ANOVA with Dunnett’s post hoc correction or two-way ANOVA between 
subjects (A, D, F) with Bonferroni post-tests. (A) At high aPC levels of Prothrombin Fragment 1+2 
(PF1+2) generation (thrombin production), there is a trend toward reduced fibrinogen in the presence of 
elevated aPC (p=0.08) (B) Fibrinogen is inversely related to rising aPC in trauma patients *p<0.05 vs. aPC 
≤3ng/ml.  (C) In trauma patients FIBTEM falls in association in rising aPC *p<0.05 vs. aPC ≤3ng/ml.  (D) High 
levels of aPC (>9ng/ml) have a significant interaction (p<0.001) on tissue Plasminogen Activator (tPA) 
associated Plasmin-Antiplasmin (PAP) generation in trauma. *p<0.05, PAP ug/L: aPC ≤3 ng/ml vs. aPC 
>9ng/ml.  (E) High aPC (aPC>9 ng/ml) was associated with lower Plasminogen Activator Inhibitor -1 (PAI-1) 
in the presence of shock (BD>4) compared to aPC ≤3 ng/ml but this did not achieve significance (p=0.10).  (F)  
Increased thrombin generation (PF 1+2) is associated with elevated D-dimers (fibrinolysis) with significantly 
greater fibrinolytic activity in the presence of high levels of aPC (interaction of aPC >9ng/ml, p<0.05) 
*p<0.05, PF 1+2 ng/ml: aPC ≤3 ng/ml vs. aPC>9ng/ml. 
 
Figure 3 
MURINE STUDIES – activated Protein C (aPC) rise after trauma hemorrhage is attenuated in Factor V 
Leiden (FVL) animals but preservation of Factor V function does not fully prevent ATC:  (A) Trauma 
Hemorrhage (TH) in Wild Type (WT) mice is associated with a significant rise in aPC (WT Time 0 [T0]: 
1.5ng/ml vs WT Time 60 mins [T60]: 10.3 ng/ml, *p<0.05) but attenuated in TMKI animals.  (B) Attenuation of 
Acute Traumatic Coagulopathy with normal Maximum Clot Firmness (MCF) in transgenic mice subject to TH 
*p<0.05 vs. WT T0.  (C) Clotting Time (CT) is prolonged after TH in WT but not thrombomodulin knock-in 
(TMKI) mice *p<0.05 WT T0 vs. WT T60 although baseline CT were significantly different between WT and 
TMKI at T0 (18 sec vs 22 sec, p<0.05).  (D) CT is prolonged in both WT and FVL mice subjected to TH 
*p<0.05, T0 vs. T60 (WT and FVL).    
 
Figure 4  
MURINE STUDIES – activated Protein C (aPC) is central to fibrinolysis in Acute Traumatic 
Coagulopathy: (A) Attenuation of fibrinolytic activity in thrombomodulin knock-in (TMKI) mice subjected to 
Trauma Hemorrhage (TH) *p<0.05 (WT: Time 0 [T0] vs. WT: Time 60 mins [T60]) (WT: T60 vs TMKI: T60).  
(B) In WT mice after TH, fibrinogen fell significantly but TMKI animals were protected from this fibrinogen 
depletion *p<0.05 (WT: T0 vs. WT: T60) and (WT: T60 vs TMKI: T60).  (C) Improved median survival times 
after TH in TMKI mice vs. WT *p<0.05. 
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Table 1 Physiological characteristics and coagulation profile of patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ROTEM defined Acute Traumatic Coagulopathy (ATC, A5 ≤35mm) vs. non-ATC (A5 >35mm).  
EXTEM: Clotting Time (CT), Clot Formation Time (CFT), Alpha angle, Amplitude (of clot) at 5 minutes 
(A5) and Maximum Clot Firmness (MCF).  Factors levels are iu/dL unless specified. Prothrombin 
Fragments 1+2 (PF 1+2), Von Willebrand Factor (vWF).  Values are mean ± 95% confidence interval or 
median (IQR).  Student t test for parametric comparison or Mann Whitney U test for non-parametric 
data. *p<0.05 
 
  Non-ATC ATC % difference 
N 250 50 - 
Median ISS 9 (4-22) 23 (10-34)* 
 Temperature (°C) 35.2 ± 0.2 35.9 ± 0.5* 2% 
Lactate (mmol/L) 2.4 ± 0.3 4.4 ± 1.2* 83% 
BD mmol/L 1.5 ± 0.5 5.2 ± 1.6* -252% 
  
   Platelets 249 ± 8 195 ± 19* 22% 
PT median (secs) 11.2 (10.7-11.8) 12.1 (11.5-13.8)* 7% 
CT (secs) 65 ± 3 78 ± 9* 17% 
CFT (secs) 87 ± 2 173 ± 19* 50% 
Alpha angle 73 ± 0 60 ± 2* -18% 
A5 (mm) 45 ± 1 29 ± 2* -36% 
MCF (mm) 61 ± 1 48 ± 2* -21% 
  
   activated Protein C (ng/ml) 2 ± 1 11 ± 4* 427% 
Protein C 90 ± 2 70 ± 6* -22% 
Antithrombin 96 ± 2 81 ± 5* -16% 
Plasmin-Antiplasmin (μg/L) 3477 ± 649 10103 ± 3018* 66% 
D dimer 20073 ± 4622 70019 ± 24756* 71% 
tPA (ng/ml) 11 (10-12) 18 (10-26) 40% 
Fibrinogen (g/dL) 2.2 ± 0.1 1.4 ± 0.2* -39% 
II 98 ± 2 79 ± 5* -19% 
PF 1+2 (pmol/L) 1371 ± 197 4231 ± 1313* 68% 
V 103 ± 3 70 ± 10* -32% 
VII 102 ± 4 88 ± 7* -14% 
VIII 289 ± 16 267 ± 44* -8% 
VIII:vWF ratio 1.3 ± 0.1 1.1 ± 0.2* -15% 
IX 120 ± 3 97 ± 8* -19% 
X 102 ± 2 98 ± 6* -19% 
XI 111 ± 3 99 ± 9* -18% 
XIII 104 ± 3 100 ± 7* -25% 
        
 




